Lonza Appoints Bertha Steinmetz Vilela as Chief Human Resources Officer
Published on 11/12/2026 at 07:00 | dgap, AD HOC NEWS| Lonza Group AG / Key word(s): Personnel 12.11.2026 / 07:00 CET/CEST Bertha Steinmetz Vilela will join Lonza as Chief Human Resources Officer, Executive Vice President and member of the Executive Committee, effective 1 January 2027. Bertha brings extensive international HR leadership experience across pharmaceuticals, biotechnology and manufacturing. Together with the recent additions of Samanta Cimitan, Matt Moorcroft and Hans Trees, this appointment further strengthens executive leadership in support of Lonza’s strategic priorities. Basel, Switzerland, 12 November 2026 – Lonza, the world’s leading contract development and manufacturing organization (CDMO), announced today the appointment of Bertha Steinmetz Vilela as Chief Human Resources Officer (CHRO), Executive Vice President and member of the Executive Committee. Bertha will join Lonza on 1 January 2027 and succeed Nicoleta Baumgärtner, who has been with the company for more than five years, serving as Chief Human Resources Officer and member of the Executive Committee since 2024, and decided to pursue a new opportunity outside of Lonza. In this role, Bertha will lead Lonza’s global human resources (HR) function, strengthen organizational effectiveness and leadership capabilities to enable business performance, while continuing to advance the company’s cultural transformation and talent agenda. This latest addition to Lonza’s Executive Committee is part of the wider evolution of Lonza's senior leadership team, including the recent appointments of Samanta Cimitan as Chief Commercial Officer, Matt Moorcroft as Chief Intelligence & Analytics Officer and Hans Trees as Global Head of Communications, all three as members of the Extended Executive Committee. Wolfgang Wienand, Chief Executive Officer, Lonza, commented: "I am very pleased to welcome Bertha to Lonza. As we continue to build and drive the transformation of One Lonza, her experience will help us strengthen our high performance culture and further develop the leadership capabilities that will enable our long-term success. Our people are at the heart of our company, and Bertha will play an important role in further advancing an environment where our teams can perform at their best and deliver for our customers and patients. I would also like to sincerely thank Nicoleta for her leadership and the important contributions she has made across two of our businesses and as Chief Human Resources Officer. After more than five years, she has decided to pursue an opportunity outside of Lonza and I wish her every success for the future." Bertha currently serves as Head of International Human Resources at Alnylam Pharmaceuticals, where she leads HR across Europe, Canada and Japan. Her experience spans organizational transformation, talent and leadership development, culture, and HR business partnering. She has worked closely with global manufacturing, commercial, and technical operations organizations, and previously held senior roles at Alexion Pharmaceuticals, Novartis and Sandoz. She has a degree in Business Administration from the Pontifical Catholic University of Minas Gerais in Brazil. Nicoleta joined Lonza in 2021, initially leading HR for the Capsules and Health Ingredients division and later for Biologics. As CHRO, she has helped successfully guide Lonza through significant organizational change and advance its global HR strategy, operating model and agenda. Previously, she held senior roles at Novartis and Roche. She will work closely with Bertha and the HR organization to ensure a smooth transition. Notes to Editors A high-resolution image of Bertha Steinmetz Vilela is available here. About Lonza Lonza is the world’s leading contract development and manufacturing organization (CDMO) dedicated to serving the healthcare industry. Working across three continents, Lonza’s global team of approximately 17,000 colleagues1 works alongside pharma and biotech companies to turn their breakthrough innovations into viable therapies. This enables customers to bring life-saving and life-enhancing treatments to patients worldwide with a combination of cutting-edge science, smart technology and lean manufacturing. Our company generated sales of CHF 3.4 billion with a CORE EBITDA of CHF 1.2 billion in Half-Year 2026. Find out more at www.lonza.com. Lonza Contact Details Victoria Morgan Head of External Communications Lonza Group Ltd Tel +41 61 316 2283 victoria.morgan@lonza.com Daniel Buchta Head of Investor Relations Lonza Group Ltd Tel +41 61 316 2985 daniel.buchta@lonza.com Additional Information and Disclaimer Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited (“SGX-ST”). Lonza Group Ltd is not subject to the SGX-ST’s continuing listing requirements but remains subject to Rules 217 and 751 of the SGX-ST Listing Manual. Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this news release due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this news release. All trademarks belong to Lonza, and are registered in the USA, EU and/or CH, or used in common law, or belong to their respective third-party owners and are used for informational purposes only. Privacy Policy link To immediately delete all the data End of Media Release View original content: EQS News |
| Language: | English |
| Company: | Lonza Group AG |
| Münchensteinerstrasse 38 | |
| 4052 Basel | |
| Switzerland | |
| Phone: | +4161 316 81 11 |
| Internet: | www.lonza.com |
| ISIN: | CH0013841017 |
| Valor: | 1384101 |
| Listed: | SIX Swiss Exchange |
| EQS News ID: | 2433252 |
| End of News | EQS News Service |
| |
en | CH0013841017 | LONZA GROUP AG | boerse | 70495353 |
